FDA Tobacco Assessment Study 2013-2016

The FDA Tobacco Assessment Study 2013-2016 Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract focuses on comprehensive scientific research examining tobacco product constituents through advanced nonclinical studies. The contract enables the Food and Drug Administration to conduct sophisticated pharmacological, behavioral, and toxicological assessments using animal models. Specifically, the vehicle supports research that evaluates the impact of various tobacco product components on physiological systems, neurotransmitter interactions, and potential abuse liability through systematic scientific protocols.

The contract's task orders, predominantly awarded to Research Triangle Institute (RTI International), typically range in value from approximately $127,000 to $1.6 million, with durations spanning several months to four years. Key task orders have included detailed studies such as determining behaviorally effective tobacco constituent doses in rodents, assessing the addictive potential of specific tobacco-related compounds like continine and anatabine, and evaluating the abuse liability of aqueous whole tobacco extract from various tobacco products. All task orders under this IDIQ were firm fixed-price or time and materials contracts, with no specific small business set-aside designations. The research appears to be conducted through specialized scientific research facilities, likely involving advanced laboratory environments capable of complex animal pharmacology and behavioral studies.